Publications

Surface CD81 supports leukemia stem cell function and reveals a therapeutic vulnerability in acute myeloid leukemia.
Gonzales F, Peyrouze P, Laurent D, Boyer T, Boukrout N, Couturier C, Houdiard S, Lisi V, Barthélémy A, Sevrin F, Plesa A, Bongiovanni A, Pottier N, Preudhomme C, Lavallée VP, Geles K, Duployez N, Berthon C, Roumier C, Cheok M. Signal Transduct Target Ther. 2026 Apr 21;11(1):145. doi: 10.1038/s41392-026-02697-2.PMID: 42014680 Free PMC article.

Targeting BMP and TAZ/TEAD mechanotransduction pathways impairs acute myeloid leukemia chemoresistance.
Barral L, Lespinasse N, Martin Cardozo C, Jeanpierre S, Bourgeois A, Rösel K, Beillard E, Laurent D, Peyrouze P, Belhabri A, Guillermin Y, Mazurier F, Cheok M, Audry-Deschamps MC, Faivre M, Maguer-Satta V, Lefort S. Leukemia. 2026 Jun;40(6):1151-1162. doi: 10.1038/s41375-026-02904-7. Epub 2026 Mar 18.PMID: 41851473 Free PMC article.

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia.
Ranasinghe D, Lin WY, Fordham SE, Alharbi A, Sunter NJ, Elstob C, Nahari MH, Xu Y, Park C, Hungate E, Quante A, Strauch K, Gieger C, Skol A, Rahman T, Sucheston-Campbell L, Hahn T, Clay-Gilmour AI, Jones GL, Marr HJ, Jackson GH, Menne T, Collin M, Ivey A, Hills RK, Burnett AK, Russell NH, Fitzgibbon J, Larson RA, Le Beau MM, Stock W, Heidenreich O, Enshaei A, Gunasinghe D, Hawking ZL, Heslop H, Nandana D, Di B, Plokhuta A, Brown IT, Allsup DJ, Houlston RS, Collins A, Milne P, Norden J, Dickinson AM, Lendrem C, Daly AK, Palm L, Piechocki K, Jeffries S, Bornhäuser M, Röllig C, Altmann H, Ruhnke L, Kunadt D, Wagenführ L, Cordell HJ, Darlay R, Andersen MK, Fontana MC, Martinelli G, Marconi G, Sanz MA, Cervera J, Gómez-Seguí I, Cluzeau T, Moreilhon C, Raynaud S, Sill H, Voso MT, Dombret H, Cheok M, Preudhomme C, Gale RE, Linch D, Weisinger J, Masszi A, Nowak D, Hofmann WK, Gilkes A, Porkka K, Milosevic Feenstra JD, Kralovics R, Wang J, Meggendorfer M, Haferlach T, Krizsán S, Bödör C, Parkin B, Malek SN, Stölzel F, Onel K, Allan JM. Blood. 2026 Apr 23;147(17):1958-1969. doi: 10.1182/blood.2025031266.PMID: 41610418

Integrating rare genetic variants into DPYD pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity.
Larrue R, Fellah S, Hennart B, Sabaouni N, Boukrout N, Van der Hauwaert C, Delage C, Cheok M, Perrais M, Cauffiez C, Allorge D, Pottier N. Pharmacogenomics J. 2024 Jan 12;24(1):1. doi: 10.1038/s41397-023-00322-x.PMID: 38216550 Free PMC article.

LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study.
Vasseur L, Fenwarth L, Lambert J, de Botton S, Figeac M, Villenet C, Heiblig M, Dumas PY, Récher C, Berthon C, Lemasle E, Lebon D, Lambert J, Terré C, Celli-Lebras K, Dombret H, Preudhomme C, Cheok M, Itzykson R, Duployez N. Blood Adv. 2023 Aug 8;7(15):4024-4034. doi: 10.1182/bloodadvances.2023010155.PMID: 37205853 Free PMC article.

UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia.
Duployez N, Vasseur L, Kim R, Largeaud L, Passet M, L'Haridon A, Lemaire P, Fenwarth L, Geffroy S, Helevaut N, Celli-Lebras K, Adès L, Lebon D, Berthon C, Marceau-Renaut A, Cheok M, Lambert J, Récher C, Raffoux E, Micol JB, Pigneux A, Gardin C, Delabesse E, Soulier J, Hunault M, Dombret H, Itzykson R, Clappier E, Preudhomme C. Leukemia. 2023 Jun;37(6):1245-1253. doi: 10.1038/s41375-023-01906-z. Epub 2023 Apr 21.PMID: 37085611 Free PMC article.

A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia.
Zeng AGX, Bansal S, Jin L, Mitchell A, Chen WC, Abbas HA, Chan-Seng-Yue M, Voisin V, van Galen P, Tierens A, Cheok M, Preudhomme C, Dombret H, Daver N, Futreal PA, Minden MD, Kennedy JA, Wang JCY, Dick JE. Nat Med. 2022 Jun;28(6):1212-1223. doi: 10.1038/s41591-022-01819-x. Epub 2022 May 26.PMID: 35618837

Ex vivo drug sensitivity profiling-guided treatment of a relapsed pediatric mixed-phenotype acute leukemia with venetoclax and azacitidine.
Gonzales F, Guilmatre A, Barthélémy A, Lapillonne H, Pottier N, Leverger G, Petit A, Cheok MH. Pediatr Blood Cancer. 2022 Oct;69(10):e29678. doi: 10.1002/pbc.29678. Epub 2022 Mar 30.PMID: 35353439 No abstract available.

Prognostic impact of ABCA3 expression in adult and pediatric acute myeloid leukemia: an ALFA-ELAM02 joint study.
Ceraulo A, Lapillonne H, Cheok MH, Preudhomme C, Dombret H, Terré C, Lambert J, Leverger G, Bertrand Y, Mortreux F, Wattel E. Blood Adv. 2022 May 10;6(9):2773-2777. doi: 10.1182/bloodadvances.2021006040.PMID: 35008099 Free PMC article. No abstract available.

Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.
Lin WY, Fordham SE, Hungate E, Sunter NJ, Elstob C, Xu Y, Park C, Quante A, Strauch K, Gieger C, Skol A, Rahman T, Sucheston-Campbell L, Wang J, Hahn T, Clay-Gilmour AI, Jones GL, Marr HJ, Jackson GH, Menne T, Collin M, Ivey A, Hills RK, Burnett AK, Russell NH, Fitzgibbon J, Larson RA, Le Beau MM, Stock W, Heidenreich O, Alharbi A, Allsup DJ, Houlston RS, Norden J, Dickinson AM, Douglas E, Lendrem C, Daly AK, Palm L, Piechocki K, Jeffries S, Bornhäuser M, Röllig C, Altmann H, Ruhnke L, Kunadt D, Wagenführ L, Cordell HJ, Darlay R, Andersen MK, Fontana MC, Martinelli G, Marconi G, Sanz MA, Cervera J, Gómez-Seguí I, Cluzeau T, Moreilhon C, Raynaud S, Sill H, Voso MT, Lo-Coco F, Dombret H, Cheok M, Preudhomme C, Gale RE, Linch D, Gaal-Wesinger J, Masszi A, Nowak D, Hofmann WK, Gilkes A, Porkka K, Milosevic Feenstra JD, Kralovics R, Grimwade D, Meggendorfer M, Haferlach T, Krizsán S, Bödör C, Stölzel F, Onel K, Allan JM. Nat Commun. 2021 Oct 29;12(1):6233. doi: 10.1038/s41467-021-26551-x.PMID: 34716350 Free PMC article.

Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML.
Duchmann M, Wagner-Ballon O, Boyer T, Cheok M, Fournier E, Guerin E, Fenwarth L, Badaoui B, Freynet N, Benayoun E, Lusina D, Garcia I, Gardin C, Fenaux P, Pautas C, Quesnel B, Turlure P, Terré C, Thomas X, Lambert J, Renneville A, Preudhomme C, Dombret H, Itzykson R, Cluzeau T. Leukemia. 2022 Mar;36(3):656-663. doi: 10.1038/s41375-021-01435-7. Epub 2021 Oct 6.PMID: 34615986 Clinical Trial.

Targeting RUNX1 in acute myeloid leukemia: preclinical innovations and therapeutic implications.
Gonzales F, Barthélémy A, Peyrouze P, Fenwarth L, Preudhomme C, Duployez N, Cheok MH. Expert Opin Ther Targets. 2021 Apr;25(4):299-309. doi: 10.1080/14728222.2021.1915991. Epub 2021 Apr 28.PMID: 33906574 Review.

Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape.
Zalmaï L, Viailly PJ, Biichle S, Cheok M, Soret L, Angelot-Delettre F, Petrella T, Collonge-Rame MA, Seilles E, Geffroy S, Deconinck E, Daguindau E, Bouyer S, Dindinaud E, Baunin V, Le Garff-Tavernier M, Roos-Weil D, Wagner-Ballon O, Salaun V, Feuillard J, Brun S, Drenou B, Mayeur-Rousse C, Okamba P, Dorvaux V, Tichionni M, Rose J, Rubio MT, Jacob MC, Raggueneau V, Preudhomme C, Saas P, Ferrand C, Adotevi O, Roumier C, Jardin F, Garnache-Ottou F, Renosi F. Haematologica. 2021 Dec 1;106(12):3056-3066. doi: 10.3324/haematol.2020.253740.PMID: 33054115 Free PMC article.

Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment.
Fenwarth L, Fournier E, Cheok M, Boyer T, Gonzales F, Castaigne S, Boissel N, Lambert J, Dombret H, Preudhomme C, Duployez N. Int J Mol Sci. 2020 Aug 6;21(16):5626. doi: 10.3390/ijms21165626.PMID: 32781546 Free PMC article. Review.